Initial study of remdesivir, an antiviral drug, shows that two-thirds of severe COVID-19 patients got better
FirstpostFor now, Remdesivir is available for compassionate use, meaning that doctors can request the drug if a patient is in a dire situation with no alternatives. Gilead, in a press release dated 22nd March, stated that it has stopped entertaining individual appeals for compassionate use, and is transitioning to expanded access programs that will streamline the process of data collection to study the effectiveness of the drug. Remdesivir was developed as a general antiviral drug which has shown a response to coronaviruses such as the ones that caused SARS and MERS in in-vitro settings. Previous studies have shown that it is safe for use in humans, and a small study on monkeys also corroborated previous evidence that it could inhibit the virus that causes MERS.